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Abstract: Oats contain unique bioactive compounds known as avenanthramides (AVAs) with
antioxidant properties. AVAs might enhance the endogenous antioxidant cellular response by
activation of the transcription factor Nrf2. Accumulation of reactive oxygen species plays a critical
role in many chronic and degenerative diseases, including osteoporosis. In this disease, there is
an imbalance between bone formation by osteoblasts and bone resorption by osteoclasts, which
is accompanied by increased osteoblast/osteocyte apoptosis and decreased osteoclast apoptosis.
We investigated the ability of the synthethic AVAs 2c, 2f and 2p, to 1-regulate gene expression in
bone cells, 2-affect the viability of osteoblasts, osteocytes and osteoclasts, and the generation of
osteoclasts from their precursors, and 3-examine the potential involvement of the transcription factor
Nrf2 in these actions. All doses of AVA 2c and 1 and 5 µM dose of 2p up-regulated collagen 1A
expression. Lower doses of AVAs up-regulated OPG (osteoprotegerin) in OB-6 osteoblastic cells,
whereas 100 µM dose of 2f and all concentrations of 2c down-regulated RANKL gene expression
in MLO-Y4 osteocytic cells. AVAs did not affect apoptosis of OB-6 osteoblastic cells or MLO-Y4
osteocytic cells; however, they prevented apoptosis induced by the DNA topoisomerase inhibitor
etoposide, the glucocorticoid dexamethasone, and hydrogen peroxide. AVAs prevented apoptosis
of both wild type (WT) and Nrf2 Knockout (KO) osteoblasts, demonstrating that AVAs-induced
survival does not require Nrf2 expression. Further, KO osteoclast precursors produced more mature
osteoclasts than WT; and KO cultures exhibited less apoptotic osteoclasts than WT cultures. Although
AVAs did not affect WT osteoclasts, AVA 2p reversed the low apoptosis of KO osteoclasts. These
in vitro results demonstrate that AVAs regulate, in part, the function of osteoblasts and osteocytes and
prevent osteoblast/osteocyte apoptosis and increase osteoclast apoptosis; further, these regulatory
actions are independent of Nrf2.
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1. Introduction
Oxidative stress is caused by the imbalance between free radical generation and the scavenging
activities of intracellular antioxidants and plays a critical role in many chronic and degenerative
diseases, including osteoporosis, cancer, and neurodegenerative diseases [1–3]. High levels of
reactive oxygen species (ROS), especially hydrogen peroxide (H2O2), in the bone/bone marrow
microenvironment play a pathogenic role in osteoporosis due to estrogen deficiency with menopause,
androgen deficiency during aging in both women and men [4], and/or glucocorticoid therapy used in
treating many inflammatory and autoimmune diseases [5]. ROS accumulation increases the number
of osteoclasts (the cells that resorb bone) by enhancing the expression by osteoblastic cells of the
pro-osteoclastogenic cytokines RANKL (Receptor Activator for Nuclear Factor κB Ligand) and TNFα
(Tumor Necrosis Factor alpha) [6–8]. ROS increase osteoclast differentiation directly by activating the
transcription factor NFATc1, which in turn increases transcription of osteoclast-specific genes [6]. ROS
also promotes osteoclast survival. On the other hand, ROS accumulation decreases the number of
osteoblasts (the cells that form bone) by inhibiting their proliferation and differentiation; and induces
premature osteoblast apoptosis [9–12]. In addition, ROS induces apoptosis of osteocytes, the most
abundant cells in the bone that orchestrate osteoclast and osteoblast function [13,14].
Two main therapeutic approaches have been developed for the management of osteoporosis:
(1) Anti-resorptive medications including bisphosphonates, estrogen replacement, and anti-RANKL
antibodies; and (2) Anabolic treatments such as daily injections of parathyroid hormone (PTH) [15].
The first approach seeks to block osteoclast formation and/or function and the second stimulates
osteoblast production and function. Although therapies for treating osteoporosis have been shown
to be effective, prevention strategies through optimal lifestyle patterns (e.g., nutrition and physical
activity) are actively being sought to help decrease the overall burden of osteoporosis and high bone
fracture risk. There is an increase in the prevalence of degenerative diseases that affect bone and
involve increased oxidative stress. Therefore, alternative therapeutic interventions that counteract
ROS effects in bone without causing harmful effects in other tissues are needed.
Nuclear factor erythroid derived 2-related factor-2 (Nrf2) plays an important role in the cellular
defense against oxidative stress by inducing enzymes that regulate oxidative stress [16,17]. Recent
studies have demonstrated that Nrf2 is an important regulator of bone homeostasis in bone cells, since
activation of Nrf2 can enhance the endogenous antioxidant response against ROS [1,16,18,19].
Increasing evidence, including epidemiological, clinical, and animal experimentation, suggests
that consumption of plant foods, containing polyphenols helps to protect against the development of
oxidative stress pathologies, including cancer, cardiovascular diseases, diabetes, neurodegenerative
diseases, and osteoporosis [20–23]. Oat is a commonly consumed whole-grain cereal that is
gaining scientific and public interest for their health benefits beyond basic nutrition [24,25]. Oats
contain phytochemicals with high antioxidant properties, among them tocopherols, tocotrienols,
phenolic compounds, phytic acid, avenanthramides (AVAs), and flavonoids and sterols in a lesser
amount [24,26,27]. AVAs are a group of alkaloid phenols uniquely found in oats [28]. These compounds
consist of an anthranilic acid derivate and a hydroxycinnamic acid derivate linked by a pseudo-peptide
bond [29], and exhibit strong antioxidant activity and anti-inflammatory and anti-proliferative
properties both in vitro and in vivo [25,30–32]. AVAs inhibit the expression of adhesion molecules and
inflammatory cytokines, such as IL-6, IL-8, and monocyte chemoattractant protein 1 in human aortic
endothelial cell cultures [33]; and inhibit the growth of human colon cancer cells in vitro [28]. Further,
dietary intake of AVAs by postmenopausal women decreased the inflammatory response induced by
physical exercise and increased the total antioxidant capacity of plasma and the superoxide dismutase
(SOD) activity of red blood cells [34]. Addition of AVAs extracts to mouse diets enhanced the hepatic
mRNA expression of Cu-Zn SOD1, Mn SOD2, and glutathione peroxidase (GPx) [35]. AVAs also
increase hemeoxygenase (HO) 1 expression in human kidney cells in a dose- and time-dependent
manner and induce the nuclear translocation of the transcription factor Nrf2 [36].
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To date, there are no studies addressing the effect of AVAs on bone cells in vitro. The aims of this
study, were to investigate the ability of the three major synthethic AVAs (2c, 2f and 2p), which differ
in the type of hydroxylcinnamic acid component (ferulic, caffeic or p-coumaric acid), to 1-regulate
gene expression in bone cells, 2-affect the viability of osteoblasts, osteocytes and osteoclasts, and
the generation of osteoclasts from their precursors, and 3-examine the potential involvement of the
transcription factor Nrf2 in these actions.
2. Material and Methods
2.1. AVAs Preparation and Cell Treatment
The synthethic AVA 2f, 2c and 2p were provided by Quaker Oats Center of Excellence (Barrington,
IL, USA). Purity was controlled by HPLC measurements (2f > 95.1%; 2c > 94.9%; 2p > 96%). AVAs
were dissolved in dimethylsulfoxide (DMSO) and added to the cell culture medium with a maximum
final DMSO concentration of 0.1%, which showed no cytotoxicity [37]. AVAs were kept as 0.05 M stock
solutions and stored at ´80 ˝C until used. Osteoblastic and osteocytic cells were treated with doses
ranging from 1 to 100 µM of the AVAs. The dose range was chosen based on previous studies using
AVAs in other cell systems [32,36].
2.2. Cell Culture
Adherent primary osteoblastic C57BL/6 wild type (WT) and Nrf2 knock-out (KO) cells were
seeded at a density of 1.5 ˆ 104/cm2 before being prepared as previously described in the scientific
literature [38–40]. The cells were cultured in growth medium consisting of α-Minimum Essential
Medium Eagle (α-MEM) supplemented with 10% fetal bovine serum (FBS), (Invitrogen, Carlsbad,
CA, USA), 1% penicillin/streptomycin (Invitrogen) and 50 mg/mL normocin (Invivogen, San Diego,
CA, USA).
Adherent OB-6 osteoblastic cells were seeded at a density of 5000 cells/cm2 in α-MEM
supplemented with 10% FBS and MLO-Y4 cells were seeded at a density of 1 ˆ 104 to 2 ˆ 104 cells/cm2
on collagen type I—coated plates in α-MEM supplemented with 2.5% FBS and 2.5% bovine calf serum
(BCS, Invitrogen), as previously published [41–43].
WT or KO bone marrow precursors were seeded at a density of 4 ˆ 105/cm2 and cultured for 48 h
in α-MEM supplemented with 15% FBS, and 1% penicillin/streptomycin and 50 mg/mL normocin.
Next, “non adherent cells”, were collected and seeded at a density of 6 ˆ 105/cm2 and cultured with
α-MEM with 10% FBS and 1% penicillin/streptomycin, and 80 ng/mL of recombinant murine soluble
Receptor Activator for Nuclear Factor κB Ligand (sRANKL) (PreproTech, Rocky Hill, NJ, USA) and
20 ng/mL recombinant murine Macrofage Colony Stimulating Factor (M-CSF) (PreproTech). Medium
was changed every 2 days for 5 days, as previously reported [44].
2.3. RNA Extraction and Quantitative RT-PCR (qPCR)
To determine the effects of AVAs on gene expression, total RNA was purified from cell
preparations using Trizol reagent (Invitrogen) according to the manufacturer’s instructions. RNA
was reverse-transcribed using a High Capacity cDNA Archive Kit (Applied Biosystems, Foster City,
CA, USA). Gene expression was analyzed by quantitative PCR using the ∆Ct method as previously
described with Mrps2 (mitochondrial ribosomal protein S2) or GAPDH (Glyceraldehyde-3-phosphate
dehydrogenase) as housekeeping genes [45,46]. The following primer probe sets were purchased
from Applied Biosystems: Collagen 1A (COL1A) (Mm00801666 g1); Osteocalcin (OCN) (AIT97T5);
Osteoprotegerin (OPG) (Mm01205928 m1); RANKL (Mm00441906 m1); Cathepsin K (Cat K)
(Mm00484036 m1); Tartrate-resistant acid phosphate (TRAPase) (Mm00475698 m1); Nrf2
(Mm00477784 m1); Mps2 (Mm00475529 m1); GAPDH (Mm99999915 g1). For the other genes, primer
probe sets were designed using the Assay Design Center of Roche Applied Science (Indianapolis,
IN, USA), and were as follows. For OSTERIX: probe 106, forward primer: gggaagggtgggtagtcatt,
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reverse primer: ctcctgcaggcagtcctc; Runt-related transcription factor 2 (RUNX2): probe 34, forward
primer: tgcctggctcttcttactgag, reverse primer: gcccaggcgtatttcaga; Calcitonin receptor (CAL R):
probe 15, forward primer: agaactggagttgggctcac, reverse primer: ggttccttctcgtgaacaggt; NAD(P)H
dehydrogenase, quinone 1 (NQO1): probe 50, forward primer: agtacaatcagggctcttctcg, reverse
primer: agcgttcggtattacgatcc; HO-1: probe 17, forward primer: tgtgttcctctgtcagcatca, reverse
primer: aggctaagaccgccttcct; SOD1: probe 49, forward primer: tgcccaggtctccaacat, reverse
primer: caggacctcattttaatcctcac. Glutathione S-transferase 1 (GSTP1): probe 105, forward primer:
ggacagcagggtctcaaaag, reverse primer: tgtcaccctcatctacaccaac.
2.4. TRAPase Staining and Osteoclast Counting
After 24 h-treatment with AVAs 2f, 2c or 2p at 1 µM or vehicle (DMSO), mature osteoclasts
differentiated from WT or KO bone marrow precursors, were examined for the activity of the
osteoclast-specific enzyme TRAPase [47]. Briefly, cells were washed with PBS and fixed in 10%
formaldehyde for 10 min. Next, cells were stained using a commercial TRAPase staining kit
(Sigma-Aldrich, St. Louis, MO, USA) and counterstained with hematoxylin according to the
manufacturer’s instructions. TRAPase + cells were considered osteoclasts if having more than 3 nuclei.
Osteoclast apoptosis was assessed by quantifying the percentage of osteoclasts that presented at least
50% condensed chromatin and dark nuclei.
Results are expressed as number of osteoclast/well or as percentage of apoptotic osteoclasts.
Images were acquired using a Zeiss Axiovert 35 microscope equipped with a digital camera.
2.5. Quantification of Osteoblastic Cell Viability
Osteoblastic cells (OB-6 and WT and KO primary cells) and osteocytic cells were seeded in a
48-well plate at a density of 1 ˆ 104 cells/well in αMEM + PSG + 10% FBS and cultured for 20 h. Next,
the medium was changed to αMEM + PSG + 2% FBS + each AVA 2c, 2f, 2p at 1, 10, or 100 µM or the
vehicle (DMSO) for 1 h. Cells were then exposed to the pro-apoptotic agents dexamethasone (10´6 M),
etoposide (50 µM), or H2O2, (50 µM) or vehicle (DMSO) for an additional 6 h. Non-adherent cells were
combined with adherent cells released from the culture dish using trypsin—Ethylenediaminetetraacetic
acid (EDTA), re-suspended in medium containing serum, and collected by centrifugation. Subsequently,
0.04% trypan blue was added and the percentage of cells exhibiting both nuclear and cytoplasmic
staining was determined using a hemocytometer. Cells that excluded the dye were considered alive,
and cells stained were considered dead. Data is reported as the percentage of dead cells [48].
2.6. Statistical Analysis
Statistical analysis was performed using SigmaPlot (Systat Software Inc., Version 12.0, San Jose,
CA, USA). All the results are presented as mean ˘ standard deviation of multiple cultures. At least
3 experiments per cell type with 5 independent replicates per experiment were performed for gene
expression and apoptosis of osteoblastic and osteocytic cells. Three independent replicates were
performed for osteoclast quantification and apoptosis. Sample differences were determined by one or
two-way ANOVA, followed by pairwise multiple comparisons using Holm-Sidak or Tukey method,
depending on the number of variables. Means were considered significantly different at p < 0.05.
3. Results
3.1. AVAs Regulate OPG and RANKL Gene Expression in OB-6 Osteoblastic and MLO-Y4 Osteocytic Cells
Gene expression analysis in OB-6 cells did not show significant changes on the expression of
the osteoblast markers OCN, RUNX2 or osterix (Figure 1A), whereas RANKL was not detected
in these cells (not shown). On the other hand, AVA 2c and 2p (1, 5 and 10 µM and 1 and 5 µM,
respectively) increased COL1A expression. Further, lower doses of the three compounds upregulated
OPG expression with more potency than higher doses in OB-6 cells, showing an inverse dose-effect
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relationship. The reason behind this unexpected biological response is not known and could be due to
the involvement of two different mechanisms or molecular mediators, one operating at lower doses
and another at higher doses of the compounds. In MLO-Y4 cells, AVAs 2f (100 µM) and 2c (at all
concentrations) downregulated the expression of RANKL, whereas AVA 2p (at 1 µM) increased it
(Figure 1B). No statistical differences were found for OPG in MLO-Y4 cells. These results suggest that





Figure  1. AVAs  (Avenanthramides)  regulate  Collagen  1A  (COL1A),  osteoprotegerin  (OPG)  and 








or  in  the  presence  of  pro‐apoptotic  agents.  One  h  pre‐treatment  with  AVA  2f,  2c  or  2p  at  the 
concentrations tested (1, 10 and 100 μM) did not affect the survival of osteoblastic cells in the absence 







dexamethasone  or  H2O2‐induced  OB‐6  and  MLO‐Y4  cell  death  (Figure  2B,C).  These  findings 
demonstrate that AVAs 2f, 2c and 2p preserve the viability of osteoblastic and osteocytic cells in vitro. 
Figure 1. s ( venanthra ides) regulate ollagen 1 ( L1 ), osteoprotegerin ( P ) and
ece tor cti ator for clear actor κ i a ( ) i osteo lastic a osteoc tic cells,
res ectively. 24-h gene expression of B-6 osteoblastic ( ), and - 4 cells ( ); treate it e icle
( ) or VA 2f, 2c or 2p. mRNA levels were measured by qPCR and corrected by Mrps2. e bars
re resent eans˘ , li t treat e t. * p < 0.05 vs. control, by One- , f ll
ir ise lti le co arisons using ol -Sidak ethod.
3.2. AVAs Do Not Affect Cell Death in the Absence of Pro-Apoptotic Agents but Prevent the Effect Induced by
Pro-Apoptotic Agents in Ob-6 Osteoblastic and Mlo-Y4 Osteocyti Cells
As f rther investigated for their effects on steoblast and osteocyte survival in th
abse ce or in the presence of r -apopto ic agents. One h pr -treatment with AVA 2f, 2c or 2p
at th conce trations tested (1, 10 and 100 µM) did not affect the surviva of osteoblastic cells in
the absence of pro-apoptot c agents (Figure 2A). As previously r po ted, the pro- popto ic agent
etoposide, incr as s he per ntage of cells with increased m mbr ne permeability [49]. However, the
three AVA compounds, at the same doses, prevented etoposide induced-apoptosis. Sin e th lowest
concentration of AVAs (1 µM) eff ctively blocked apoptosis of osteblastic cells, this dose was used for
the next se of experiments, a ming to examine whether AVAs regula e su vival in the presence of the
pro-apoptotic agents d xamethasone or H2O2. Six h-treatment with d xamethaso e or H2O2 i cre sed
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significantly the percentage of cells exhibiting trypan blue uptake; however 1-h pre-treatment with
AVAs prevented dexamethasone or H2O2-induced OB-6 and MLO-Y4 cell death (Figure 2B,C). These
findings demonstrate that AVAs 2f, 2c and 2p preserve the viability of osteoblastic and osteocytic cells
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cells  (Figure  3A).  Surprisingly, AVAs were  also  effective  in  promoting  survival  in  primary KO 
osteoblastic  cells  (Figure 3B). Moreover, AVA 2f was more effective  to decrease  cell death  in  the 
absence or in the presence of pro‐apoptotic agents, in primary KO osteoblastic cells compared to WT 




i re 2. s t i ce a t sis a re e t cell eat i ce r a t tic a e ts i
ste l stic ste c tic cells. ( ) ell e t s e i e i ste l stic cells retre te f r -
it i l ( tr l) r iff r t f f, , f ll r t i l ( ,
i t l lf i ( )) or etoposide for 6-h; (B,C) Cells wer treated with vehicle (control) or 1 µM
AVAs for 1 h, followed by 6 h-treatment with the indicated compounds. Vh, vehicle; Eto, etoposide;
Dex, dexamethasone or H2O2. Cell death was assessed by trypan blue uptake. Bars re res nt the
mean ˘ SD of n = 6 indepe dent wells/tr atment. * p < 0.05 vs. Vh control, and lines connect
ditions with significant di ferences by On -Way ANOVA, followed by Tukey method.
3.3. The Survival Effect of vas in steoblastic Cells oes ot Require rf2 Expression
e exa ined hether activation of the rf2 path ay, a key co ponent of the antioxidant
cellular defense echanism, was involved in the protective effects of VAs on osteoblastic cells,
by comparing the effects of AVAs in WT or Nrf2 KO osteoblastic cells. Pre-treatment with AVA
2f, 2c or 2p prevented cell death induced by etoposide, dexamethasone or H2O2 in WT primary
osteoblastic cells (Figure 3A). Surprisingly, AVAs were also effective in promoting survival in primary
KO osteoblastic cells (Figure 3B). Moreover, VA 2f was more effective to decrease cell death in the
absence or in the presence of pro-apoptotic agents, in pri ary osteoblastic cells co pared to T
cells. These findings demonstrate that the survival effect of AVAs on osteoblastic cells does not require
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Nrf2 expression. Consistent with this conclusion, the mRNA expression of the Nrf2 target genes,
cytoprotective enzymes SOD1, HO-1 or GSTP1 were not affected by treatment with AVAs in MLO-Y4
















osteoclasts  in KO  cultures  to  reach  levels  found  in WT  cultures. Consistent with  the  increased 




Figure 3. The survival effect of AVAs in osteoblastic cells does not require the expression of Nrf2.
(A,B) Cell death was quantify by trypan blue uptake. Bars represent means ˘ SD of n = 6 samples per
treatment. * p < 0.05 vs. cells treated with vehicle, by One-Way ANOVA, followed by Tukey method;
(C) MLO-Y4 osteocytic cells mRNA levels were measured by qPCR and corrected by Mrps2. The bars
represent means ˘ SD, n = 5 replicates/treatment. * p < 0.05 vs. control, and lines connect conditions
with significant differences by One-Way ANOVA, followed by pairwise multiple comparisons using
Holm-Sidak method.
3.4. Nrf2 Is Not Required for the Regulation of Gene Expression and Survival of Osteoclasts by AVAs
We next examined the effect of AVAs on osteoclasts and the potential requirement of Nrf2. Bone
marrow osteoclast precursors lacking Nrf2 (KO cultures) treated with vehicle (control) produced
30% ˘ 2% more osteoclasts than WT control cultures (Figure 4A,B). In addition, KO control cultures
exhibited lower number of apoptotic osteoclasts compared to WT control cultures (13% ˘ 2% vs.
23% ˘ 2% for KO and WT, respectively). Altho gh AVAs did not affect the umber or the percentage
of dead osteoclasts in WT cultures (Figure 4A,B), AVAs 2f and 2p increa ed the pe centage of apoptotic
osteoclasts in KO ultures to reach levels found in WT cultures. Co sistent with the increased osteoclast
number observed in KO cultures, the expression of genes that characterize mature osteoclasts, including
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Cat K, CAL R and TRAPase, were higher in these preparations compared to WT cultures (Figure 4C).
AVA 2f did not affect osteoclastic gene expression either in WT control or KO cultures. AVA 2c increased
CAL R expression in WT cultures. Further, AVA 2p increased the expression of CAL R and TRAPase
in WT cultures, whereas it decreased CAL R in KO cultures. This latter effect is consistent with the


















and  treated  for  24‐h with AVAs.  (A) Osteoclast  number  and  percentage  of  dead  osteoclasts were 
quantified by TRAPase‐Hematoxylin staining n = 3 replicates/treatment; (B) Representative images of 
osteoclasts stained for TRAP are shown; (C,D) Gene expression in Nrf2 WT and KO cells. mRNA levels 
were  measured  by  qPCR  and  corrected  by  GAPDH.  Bars  represent  means  ±  SD,  n  =  5 
replicates/treatment.  * p < 0.05 versus  cells  treated with vehicle by One‐Way ANOVA,  followed by 





was  the  only  antioxidant  enzyme whose  expression was  dependent  on Nrf2,  as mRNA NQO1 
transcripts were markedly reduced in KO compared to WT cultures (Figure 4D). In contrast, HO‐1 
and  SOD1  expressions  were  similar  in  cultures  of  both  genotypes.  AVA  2p  increased  NQO1 
expression in WT, but not in KO cultures. Similar results were obtained with AVA 2f and 2c, although 
the increase in NQO1 expression did not reach significance in WT cultures. AVAs did not alter HO‐
1  in  cells of  either genotype.  In  contrast, AVAs  increased SOD1  expression  in both WT  and KO 
cultures, with AVA 2p exhibiting the strongest effect. Taken together, these results show a differential 





















[63].  In our  study,  the  lowest doses of all  three AVAs  increased OPG  in OB‐6 cells,  suggesting a 
beneficial effect of AVAs by inhibiting osteoclast differentiation. Furthermore, we found that AVAs 2f 
Figure 4. AVAs effect on the regulation of osteoclast gene expression and survival does not require
Nrf2 expression. Non adherent cells were differentiated into osteoclasts by treatment with Macrofage
Colony Stimulating Factor (M-CSF) and Receptor Activator for Nuclear Factor κB Ligand (sRANKL)
for 5 days and treated for 24-h with AVAs. (A) Osteoclast number and percentage of dead osteoclasts
were quantified by TRAPase-Hematoxylin staining n = 3 replicates/treatment; (B) Representative
images of osteoclasts stained for TRAP are shown; (C,D) Gene expression in Nrf2 WT and KO
cells. mRNA levels were measured by qPCR and corrected by GAPDH. Bars represent means ˘ SD,
n = 5 replicates/treatment. * p < 0.05 versus cells treated with vehicle by One-Way ANOVA,
followed by pairwise multiple comparisons using Holm-Sidak method. # p < 0.05 versus the
corresponding WT treatment by Two-Way ANOVA, followed by pairwise multiple comparisons
using Student-Newman-Keuls method.
s expected, cultures exhibit ini al expression of rf2 co pare to T cultures
(Figure ). s i not change Nrf2 expressio in cultures of either genotype. In addition,
NQO1 was the o ly antioxidant enzyme whose expression was dependent on Nrf2, as 1
transcripts were markedly reduced in KO compared to WT cultures (Figure 4D). In co trast, HO-1 and
SOD1 expressions were similar in cultures of both genotypes. AVA 2 increased NQO1 xpression in
WT, but not i KO cultures. Similar results were obtained ith AVA 2f and 2c, although the increase in
NQO1 expr ssion did not reach significance in WT cultures. AVAs did not alter HO-1 in cells of either
genotype. In contrast, AVAs increased SOD1 expression in both WT and KO cultures, with AVA 2p
exhibiting the strongest effect. Taken togeth r, these results show a differential effect of AVAs on the
expression of antioxidant enzymes that depen s on the enzyme an of the presence or abs nce of Nrf2.
4. Discussion
The results of this study demonstrate that AVAs, compounds found uniquely in oats, regulate
the expression of some genes in osteoblastic cells and affect the life span of the bone cells, osteoblasts,
osteocytes and osteoclasts. Remarkably, AVAs were similarly effective in WT or Nrf2 KO cells to exert
their anti-apoptotic effects on osteoblastic cells and their pro-apoptotic effects on osteoclasts. Although
previous studies have shown that AVAs exert cytoprotective effects on other cell types in vitro [50,51],
to our knowledge, this is the first study that evaluates the effects of AVAs on bone cell survival.
Osteoblasts express extracellular matrix proteins such as alkaline phosphatase, OCN and COL1A
during the cell proliferation, matrix maturation, and mineralization phases [52]. The levels of
mRNA expression of these osteoblast markers allows distinguishing the stages of differentiation
and maturation of osteoblasts. COL1A among others, is secreted during the early stage of osteogenic
differentiation, whereas OCN is a marker of a mature osteoblasts [53–55]. Our results revealed
that AVA 2c and 2p potentially enhanced osteogenic differentiation by increasing the expression
levels of COL1A. Cells of the osteoblastic lineage, osteoblasts, osteocytes and stromal/osteoblastic
cells, play an important role in bone remodeling by expressing pro- and anti-osteoclastogenic
cytokines [56–59]. These cells express the master osteoclast differentiation factor RANKL in response to
osteoclast-stimulating hormones and cytokines, including PTH, tumor necrosis factor and interleukin-1;
and they also express the RANKL decoy receptor OPG that inhibits osteoclastogenesis [45,58,60–62].
OPG protects bone from excessive resorption by preventing RANKL from binding to its receptor
(RANK) [63]. In our study, the lowest doses of all three AVAs increased OPG in OB-6 cells, suggesting
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a beneficial effect of AVAs by inhibiting osteoclast differentiation. Furthermore, we found that AVAs 2f
and 2c decrease RANKL expression in MLO-Y4 osteocytic cells. Taken together these findings suggest
that AVAs could modulate osteoclastogenesis by altering the expression of RANKL and OPG. Future
studies are required to examine the relevance of our in vitro findings for the potential beneficial effects
of AVAs on the skeleton in vivo; and the mechanistic basis of the differential effects of individual AVAs
on bone cell gene expression.
Apoptosis plays a central role in the maintenance of skeletal mass and strength and several
molecular mechanisms are involved in apoptosis regulation in bone cells [64,65]. Changes in the
prevalence of osteoblast apoptosis have a significant impact in the number of osteoblasts present at
sites of bone formation and their function [66]. Hence, increased osteoblast apoptosis is at least partially
responsible for the decreased bone formation associated with the osteopenia induced by glucocorticoid
excess [67], and conversely, inhibition of osteoblast apoptosis might contribute to the anabolic effect
of intermittent administration of PTH [40,68]. Several studies have emphasized the importance of
osteocyte viability for the maintenance of bone structure and strength [69]. Accumulation of apoptotic
osteocytes preceded the increase in osteoclasts, suggesting a cause-effect relationship between dead
osteocytes and bone resorption [70,71]. Thus, the increased bone fragility that occurs as consequence
of glucocorticoid excess, sex steroid deficiency, immobilization and aging, is associated with increased
osteoblast and osteocyte apoptosis [72]. It is known that osteoclasts die by apoptosis after completing
a bone resorption cycle and that the majority of osteoblasts also die, whereas the remainders become
lining cells or osteocytes. Osteocytes also can die prematurely with devastating consequences for
bone fragility. Furthermore, it is recognized that systemic hormones, local growth factors, cytokines
and pharmacological agents, as well as physical stimuli such as mechanical forces regulate the rate of
bone cell apoptosis [66]. The data presented in this report indicate that AVAs do not induce apoptosis
of osteoblastic or osteocytic cells. However, AVAs inhibit the effect of several pro-apoptotic stimuli.
Moreover, AVA 2p induced apoptosis of KO osteoclasts. Similar to our findings with osteoclasts, AVA
2p induced apoptosis of the human cervical cancer cell line HeLa [73]. Because exaggerated ROS
induces apoptosis of osteoblasts and osteocytes whereas it preserves osteoclast viability, it is possible
that AVA actions are mediated by their antioxidant properties.
The Nrf2 pathway constitutes one of the major cellular defense mechanisms against oxidative
stress, as evidenced by the fact that mice lacking Nrf2 are prone to the damaging effects of oxidative
stress in different tissues [18,74]. The Nrf2 signaling pathway is emerging as a critical factor in the
regulation of bone metabolism [75]. Deletion of Nrf2 suppresses antioxidant enzymes and elevates
the intracellular ROS level in osteoclasts, increasing osteoclast number and stimulating osteoclast
activity [76,77]. Consistent with this previous evidence, we found that bone marrow precursors in KO
cultures presented higher number of osteoclasts and that the lack of Nrf2 also enhances osteoclast
survival. Furthermore, we showed that AVAs induce osteoclast apoptosis in KO cultures. These
findings are consistent with the fact that ROS is required for osteoclast generation and survival. On
the other hand, WT, as well as KO primary osteoblastic cells treated with AVAs, were protected
from apoptosis. This finding suggests that the pro-survival effect of AVAs on osteoblastic cells as
well as the pro-apoptotic effect on osteoclasts does not require Nrf2 expression. Collectively, these
outcomes demonstrate that AVAs, at the concentrations and exposure times tested, act by mechanisms
independent of Nrf2 in bone cells of both osteoblastic and osteoclastic lineage. Future experiments are
needed to determine whether the effective concentrations of AVAs in the current study are found in
the bone tissue after dietary intakes of these compounds.
We also found that NQO1 was the only antioxidant enzyme which expression is strictly dependent
on Nrf2; and that the expression of other antioxidant enzymes, including HO-1 and SOD1 was still
high in KO cultures, strongly suggesting that they are controlled by alternative factors. AVAs did not
have a major effect on the expression of these enzymes, recognized as Nrf2 target genes. However,
AVA 2p increased NQO1 in WT cultures and SOD1 in both WT and KO cultures, suggesting that it
activates the endogenous antioxidant defense by a mechanism that does not involve Nrf2.
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Our results demonstrating actions of AVA independent of Nrf2 appear to be inconsistent with
findings demonstrating that the increase in the expression of the antioxidant enzyme HO-1 induced by
AVAs is associated with Nrf2 nuclear translocation in human kidney cells [36]. This difference could
be due to the cell type, as well as the dose and time of treatment.
5. Conclusions
In conclusion, although further studies are needed to examine the mechanism(s) by which AVAs
regulate bone cell survival, our findings demonstrate that AVAs affect gene expression in bone cells
in vitro, as well as cell viability, preventing osteoblastic and osteocytic cell apoptosis and increasing
osteoclast apoptosis; and that these effects of AVAs in the studied cells are not mediated by Nrf2.
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